APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration.

CONCLUSIONS: X-82 oral therapy in combination with pro re nata anti-VEGF injections showed non-inferiority in visual acuity outcomes while achieving a dose-dependent decrease in the number of anti-VEGF injections compared with placebo. Given the limited tolerability and safety issues observed, X-82 does not have a sufficient benefit to risk profile in treatment of patients with AMD.
PMID: 32586932 [PubMed - as supplied by publisher]

Source: The British Journal of Ophthalmology - June 24, 2020 Category: Opthalmology Authors: Cohen MN, O'Shaughnessy D, Fisher K, Cerami J, Awh CC, Salazar DE, Rosenfeld P, Heier JS Tags: Br J Ophthalmol Source Type: research